Fink, Klein and Kramer (1) have previously reported the use of chlorpromazine-procyclidine, imipramine and placebo in a six-week fixed dosage, random assignment, do ubi e-bIin d , controlled study of depressive patients. This reference includes a review of the literature concerning the use of phenothiazines in the treatment of depression.
This previous study is at present being replicated exactly in an effort to expand the number of subjects so that the conclusions may be more securely founded. Also increasing the number of subjects allows for the possibility of subdividing the sample so as to discover predictive correlates of improvement.
Method
All patients referred for drug therapy in a voluntary psychiatric hospital, regardless of diagnosis or prevailing target symptoms, were randomly assigned to one of three fixed dosage treatment regimens. Following the study period, the pre-treatment records of all patients were examined and diagnoses assigned by the authors. Twenty-nine patients were classified as manic-depressive depressed and six as involutional depression. In our present study diagnosis is made prior to treatment. Twelve more depressive cases, nine manic-depressive depressed and three involutional reactions were diagnosed out of a total group of eighty patients. The study is being continued. Since it would not be useful to report separately on these twelve patients the combined data on all forty-seven patients is reported here.
Twenty subjects received chlorpromazine with procyclidine** added; sixteen received imipramine; and eleven placebo. To make the 'double-blind' study a reality, as well as to obviate the occurrence of extrapyramidal symptoms, procyclidine was prophylactically used as an adjunct to chlorpromazine administration. ,The dosage schedule is given in Table I .
Various behavioural rating scales were used as well as a six-point clinical outcome rating by two project psychiatrists who rated each patient from -2 for worse, through zero for unchanged, to +3 for recovered. In 81% of the original sample (144 patients), the two independent clinical ratings were within one step, and these were added for a composite score. In the remaining patients, a consensus score was derived after discussion. In the .. ..Kemadrin. present study three judges are used, including the patient's therapist. A 'rate and reactivity' score derived from the Lorr MSRPP was analyzed as relevant to this clinical problem. The patients were divided into two groups by their initial pretreatment 'rate and reactivity' score, derived by totalling the MSRPP bipolar item numbers, 7, 8, 23, 31 and 36. Patients with scores greater than 14 were considered high in rate and reactivity (hyperactive), and those below 14 were considered low (hyperactive).
The Lorr MSRPP Factor E (Melancholy Agitation) and Clyde Mood Scale 'Sleepy' (sleep, drowsy, fatigued, tired) as rated by each patient's resident psychiatrist, two scores relating to the initial degree of motor activity, were also analyzed. The Melancholy Agitation factor was dichotomized at the median initial score of 18.3 and the Clyde 'Sleepy' score was dichotomized at the mean initial score of 47.1.
In addition, the complete case data was reviewed and the diagnosis of retarded depression or agitated depression determined.
Results
Several behavioural response patterns occurred in each treatment group. With imipramine, patients showed little change during the first two weeks except for transient complaints of drowsiness. Thereafter, there was a steady brightening of mood, decrease of complaints and agitation, increased interest in the environment and greater participation in social activities. Eight patients showed this pattern to various degrees. Four patients exhibited verbal denial and minimization of symptoms. Three showed a manic response and one a mood elevation followed by an intense erotic transference. These effects were prominent by the fourth and fifth week.
Eleven patients receiving chlorpromazine-procyclidine showed an immediate progressive decrease in agitation, a rapid alleviation of insomnia followed usually in one to two weeks by an abrupt elevation of mood. Two patients complained of somatic symptomatology so marked as to be incapacitating.
Two of the eleven patients receiving placebo developed sustained mood elevation and were considered greatly improved, one was considered moderately improved but quickly relapsed, while little behavioural change was seen in the remaining eight. In these, mood fluctuations and relief of dysphoric feelings alternated with periods of anxiety and depression, often within a span of days.
Change Scores
Clinical outcome ratings are significantly better with both chlorpromazineprocyclidine and imipramine than with placebo (Table II) . The clinical effectiveness of chlorpromazine-procyclidine is understated in that two negatively evaluated cases developed somatic complaints leading to a refusal to participate in activities while receiving the 1200 mg dose. In each case, after the fixed-dosage study period was completed, reduction of daily dosage to 300 mg was associated with a sustained clinical improvement.
Similarly the valuable effects of imipramine are understated since in two of the three manic responses, there was such hostility that the patients were rated negatively. Following the fixed dosage period the reduction of dosage combined with phenothiazine medication produced a sustained clinical improvement.
Pre-Treatment Scores
It is frequently suggested that chlorpromazine may be of value in agitated depressive states but that it has either limited value or is contraindicated in the treatment of retarded depressive subjects for whom imipramine is recommended. The clinical ratings of subjects divided according to the initial interview rate and reactivity score shows both imipramine and the chlorpromazine-procyclidine combination to be associated with more Placebo us. Imipramine Placebo us. Chlorpromazine-Procyclidine favourable ratings among the hypoactive patients. In addition, the rate and reactivity score increased in the hypoactive subjects and decreased in the hyperactive subjects in each treatment group, reflecting a 'normalizing' effect rather than an 'activating' or 'tranquillizing' effect for each therapeutic agent. Analyses of the effects of initial position on outcome as rated in the interview derived Sleepy and Melancholy Agitation Scales, showed similar trends with both drugs producing 'normalizing' effects. However, it was noted that the doctor's ratings of interview behaviour was not entirely concurrent with the general behaviour of the patient as reported by relatives and ward staff. Many patients were slow, unproductive and compliant in interview with the high status doctor, but demanding, complaining and restless in the ward setting. To deal with this issue the drug effects were compared within the 31 agitated depressives and 16 retarded depressives (Tables III and IV) . The trends evident for the entire group are maintained for the agitated depressives. The retarded group is too small for statistical analysis although the trends are not sharply dissimilar. 
Summary
Based on the early reports of the successful treatment of depressive states with chlorpromazine, 47 voluntarily hospitalized psychiatric patients referred for drug therapy, were rando~ly assig~ed to one of three treatment regImens. SIxteen depressive patients received imipramine, 11 placebo and 20 a co~~ina~ion~f chlorpromazine and procychdme in a six-week, fixed dosage schedule.
On clinical behavioural ratings, both the chlorpromazine -procycli?in~com-bination and imipramine had significantly better therapeutic results than placebo.
These Ces observations concordent avec les rapports preliminai~~s vo~lant .que Ie traitement des conditions depressives par la chlorpromazine peut etre rendu pl~s efficace par l'addition d'un agent anticholinergique anti-parkinsonien. II s'avere evident que les depressions agitees peuvent etre traitees avec succes par la chlorpromazine-procyclidine. II faudra encore plus de donnees pour arri.ver.a evaluer ce traitement dans son application pour les depressions retardees,
